Learn how targeted therapies can help balance blood sugar levels and boost metabolic health.
The study aimed to investigate the effects of molecular hydrogen (H2) treatment on type 2 diabetes mellitus (T2DM) in rats.
Rats were fed a high-fat diet for four weeks, followed by injections of low-dose streptozotocin (STZ) to induce T2DM.
T2DM induction led to increased fasting blood glucose levels, insulin resistance, and abnormal lipid metabolism, along with oxidative stress in the rats.
H2 treatment improved glucose metabolism by increasing hepatic glycogen synthesis and lowering fasting blood glucose levels. It also improved insulin sensitivity without affecting insulin levels and restored normal lipid metabolism by decreasing triglyceride, total cholesterol, and LDL cholesterol levels, while increasing HDL cholesterol levels.
Yes, H2 treatment increased superoxide dismutase (SOD) activity, indicating improved antioxidant capacity, and decreased serum malondialdehyde (MDA) levels, a marker of oxidative stress.
H2 treatment preserved the morphology of pancreatic islets and glomeruli, potentially indicating protection against T2DM-induced damage.
Yes, H2 treatment effectively suppressed the activation of the toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MyD88)/nuclear factor kappa B (NF-κB) signaling pathway, suggesting anti-inflammatory effects in T2DM.
H2 treatment shows promise as a therapeutic approach for managing T2DM by improving glucose and lipid metabolism, alleviating oxidative stress, preserving tissue morphology, and suppressing inflammatory signaling pathways. Further research is needed to validate these findings and explore underlying mechanisms.